NEW YORK, May 2 – Buoyed by strong sales of its genetic mutation testing kits, Transgenomic’s first quarter 2001 life science revenues rose 66 percent to $7.9 million, compared with $4.7 million in life sciences revenues for the previous-year quarter, the company said Wednesday.